Website: https://panoramamedicine.com
Develops therapeutic interventions for RNA defects using genomics, big data, and computing with a proprietary genome-wide drug screening platform.
VentureRadar Research / Company Website
Panorama integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in a wide variety of disease. Our proprietary genome-wide drug screening platform targets diseases treatable through modulation of RNA splicing.
VentureRadar Research / Company Website
Associated sectors:
Biotechnology; Bioinformatics; Genetics & Genomics; Biotech;
Similar Companies:
Immuneering
USA
Publicly Traded
Immuneering’s lead product candidate IMM-1-104 aims to achieve universal-RAS activity that selectively?impacts?cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily dosing. IMM-1-104 is currently being evaluated in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415 as well as several early-stage programs.
Eagle Genomics
United Kingdom
Privately Held
Eagle Genomics (Eagle) is an expert provider of bioinformatics software and services across a wide range of the life science and other sectors. Eagle’s current offering includes ElasticAP, a SaaS (Software-as-a-Service) subscription platform, which will enable customers to analyse data through the Cloud using Eagle’s expertise. The Company also plans to expand its consulting business by pushing further into non-traditional areas for bioinformatics such as consumer goods, food safety and animal health. Eagle has over 30 customers worldwide from the large pharmaceutical, biotechnology, crop science, bio-fuels, personal hygiene, and animal health sectors.
Envisagenics
USA
Privately Held
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. The company's mission is to boost the creation of new therapies for human diseases by reducing the complexity of biomedical big data into plausible solutions. Envisagenics focuses on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors and more remain to be discovered. Envisagenics' breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. The company will use its software to identify new splicing errors causative of the disease, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Envisagenics' in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
MedGenome
India
Privately Held
MedGenome is a high-end genomics company dedicated to helping doctors around the world implement cancer treatment strategies tailored specifically to each patient's unique genetic code. Through its work with thousands of doctors, hospitals, and patients across India, MedGenome uses the power of genetic homogeneity to develop next-generation DNA sequencing techniques and sophisticated data analytics capabilities that significantly improve disease risk assessment, management, treatment and patient outcomes. Its proprietary OncoMD database offers insight into more than 1.2 million cancer-related mutations via a searchable catalogue that helps physicians and hospitals pinpoint patients' mutation hotspots, identify prevalent cancer types, flag potential sensitivity to therapies, and link mutations to open clinical trials. Incubated in 2012 from SciGenom Labs, the company is backed by a team of industry veterans with deep experience in genomics and Big Data technologies.
EdiGene
China
n/a
EdiGene is a global, clinical-stage biotechnology company focused on translating gene editing technologies into transformative therapies for patients with serious genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies.